GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » FFO

Genor Biopharma Holdings (HKSE:06998) FFO


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings FFO?

FFO (Funds from operations) only applies to REITs.


Genor Biopharma Holdings Business Description

Traded in Other Exchanges
Address
690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Executives
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hhjh Holdings Limited 2101 Beneficial owner
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Bio Investment Fund, L.p. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager
Hh Bio Investment Fund L.p. 2201 Interest of corporation controlled by you
Temasek Capital (private) Limited
Aranda Investments Pte. Ltd.
Seletar Investments Pte Ltd
Walga Biotechnology Limited 2101 Beneficial owner
Shang Hai Wo Jia Sheng Wu Ji Shu You Xian Gong Si 2201 Interest of corporation controlled by you
Yun Nan Wo Sen Sheng Wu Ji Shu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited